Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. The findings do not support CBD as an effective standalone treatment for fibromyalgia pain based on current evidence. Clinicians should communicate these results to patients who are considering or already using CBD specifically for fibromyalgia symptom management.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized controlled trial provides the first rigorous evidence evaluating cannabidiol’s efficacy in fibromyalgia, a condition where current pharmacotherapies have limited effectiveness and high side effect burdens. Given the widespread off-label use of CBD in fibromyalgia patients, robust efficacy and safety data from this double-blind design directly inform evidence-based prescribing practices and patient counseling. The findings will clarify whether CBD represents a viable therapeutic option or whether current usage reflects placebo response, fundamentally shaping clinical decision-making for a patient population with few validated treatment alternatives.
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
? This Danish randomised controlled trial addresses a meaningful evidence gap by directly testing CBD against placebo in fibromyalgia, a condition where patients often seek cannabis-based treatments despite limited rigorous data. The single-centre design and recruitment from a specialised clinic may limit generalisability to broader fibromyalgia populations, and we should await the full results regarding primary efficacy outcomes and safety signals before drawing firm conclusions about CBD’s clinical utility in this indication. The study’s double-blind, placebo-controlled methodology is methodologically sound, though fibromyalgia’s heterogeneous presentation and high placebo response rates in pain trials warrant careful interpretation of any observed differences. Given the widespread off-label use of CBD for fibromyalgia, a well-executed trial providing clarity on efficacy and tolerability will help clinicians counsel patients more precisely about realistic expectations and alternatives, ultimately supporting more evidence-based rather than assumption-driven prescribing decisions.
Have thoughts on this? Share it:
